Xenon Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for azetukalner (XEN1101) as adjunctive treatment for focal seizures in adults with epilepsy, based on ...

The FDA has granted fast track designation to Scholar Rock’s apitegromab (Isembyld), a muscle-targeting therapy recently approved for the treatment of spinal muscular atrophy (SMA), for patients ...

A retrospective cohort study found DTI-ALPS, a glymphatic function marker, did not independently predict survival in glioblastoma beyond extent of resection and sex. A published protocol outlines the ...

Olfactory dysfunction, dysautonomia, mood disturbance, and motor deficits disproportionate to dopaminergic denervation may serve as markers of amyloid-β positivity in newly diagnosed Parkinson disease ...

Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions ...

A retrospective cohort study found DTI-ALPS, a glymphatic function marker, did not independently predict survival in ...

Xenon Pharmaceuticals submitted an FDA New Drug Application for azetukalner, a KV7 potassium channel opener, as adjunctive therapy for focal seizures in epilepsy. Marketed as Fayuvi, the 1-time AAV9 ...

The FDA granted priority review to satralizumab for MOGAD, positioning it to become the first approved treatment for the rare ...

Foundational health behaviors reduce migraine burden, but frequent or disabling attacks commonly require preventive treatment ...

Approval hinged on CSF heparan sulfate lowering, reflecting feasibility constraints for randomized neurodevelopmental trials in an ultra-rare, rapidly progressive neuronopathic disorder. Transpher A ...

Welcome to NeurologyLive® 's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive 's widespread coverage in ...

A new study suggests excessive daytime sleepiness in obstructive sleep apnea may be associated with cognitive impairment and ...